The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk of rash with nilotinib: A systematic review of the literature and meta-analysis.
Aaron Mark Drucker
No relevant relationships to disclose
Shenhong Wu
No relevant relationships to disclose
Ellin Berman
Research Funding - Novartis
Mario E. Lacouture
Consultant or Advisory Role - Advancell; Amgen; AVEO; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; ImClone Systems; Onyx; OSI Pharmaceuticals; Pfizer; Roche
Honoraria - Advancell; Amgen; AVEO; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; ImClone Systems; Onyx; OSI Pharmaceuticals; Pfizer; Roche
Research Funding - Cytotech; GlaxoSmithKline